Evidence map›Paper›PMID 41245763›Full record

ReviewChemical science2025

Multivalently engineered glyco-nanoplatforms for targeted therapy and diagnostics.

Xiao-Lin Zhang, Han Ding, Jia-Yi Zheng, Hongzhi Cao, Xue-Wei Liu

Abstract readReview
In one paragraph

Review in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiao-Lin ZhangSchool of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University Singapore 637371 Singapore xuewei@ntu.edu.sg.
Han DingSchool of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University Singapore 637371 Singapore xuewei@ntu.edu.sg.ORCID https://orcid.org/0000-0003-3170-0723
Jia-Yi ZhengSchool of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University Singapore 637371 Singapore xuewei@ntu.edu.sg.
Hongzhi CaoKey Laboratory of Marine Drugs of Ministry of Education, Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China Qingdao 266003 China.
Xue-Wei LiuSchool of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University Singapore 637371 Singapore xuewei@ntu.edu.sg.ORCID https://orcid.org/0000-0002-8327-6664

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glyco-nanoplatforms have emerged as powerful nanosystems that exploit glycan-lectin interactions for targeted therapy, diagnostics, and immunomodulation. By presenting glycans in multivalent architectures, glyco-nanoplatforms enhance binding affinity and specificity toward glycan-recognizing receptors on mammalian and bacterial cells. This perspective highlights recent advances in the design and synthesis of glyco-nanoplatforms across four key classes, including glyco-gold nanoparticles, glycopolymer-based nanoplatforms, glyco-functionalized quantum dots, and glycan-based magnetic nanocomposites. Through diverse synthetic strategies, structurally distinct glyco-nanoplatforms have been developed with improved binding affinities, stability, and biodistribution. Moreover, we further discuss their diverse biomedical applications in both mammalian and bacterial cells, ranging from targeted cancer therapy and biosensing to immunomodulation and antimicrobial treatment. Finally, we outline key challenges and provide an outlook on further directions in this field, aiming to unlock the therapeutic potential of the glyco-code.

Identifiers

PMID41245763
PMCPMC12614179

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.